# Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

> **NCT07067905** · EARLY_PHASE1 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma and Glioblastoma

## Interventions

- **DRUG:** 68Ga-XT771

## Key facts

- **NCT ID:** NCT07067905
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067905, "Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07067905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*